DC/AML Vaccine + Decitabine for AML
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must not be on any non-FDA approved study agents and should not require active treatment with systemic steroids or immunosuppressive therapy for autoimmune or inflammatory disorders.
What data supports the effectiveness of the DC/AML Vaccine + Decitabine treatment for AML?
Research shows that dendritic cell vaccines, like the DC/AML vaccine, can help the immune system fight leukemia by increasing specific immune responses in patients with AML. Additionally, a study found that a similar dendritic cell vaccine was well tolerated and led to encouraging long-term survival rates in AML patients.12345
Is the DC/AML Vaccine + Decitabine treatment generally safe for humans?
Research on dendritic cell vaccines for acute myeloid leukemia (AML) shows that they are generally well tolerated, with no severe adverse side effects reported in several studies. Patients experienced mild and temporary reactions at the injection site, and the treatment was considered safe in both younger and older AML patients.13678
How is the DC/AML Vaccine + Decitabine treatment different from other treatments for AML?
The DC/AML Vaccine + Decitabine treatment is unique because it combines a dendritic cell-based vaccine, which uses the patient's own immune cells to target leukemia, with Decitabine, a drug that modifies DNA to enhance immune response. This approach aims to improve the immune system's ability to recognize and attack leukemia cells, offering a novel strategy compared to traditional chemotherapy.2391011
What is the purpose of this trial?
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML).The interventions involved in this study are:* Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)* Decitabine, a chemotherapy drug
Research Team
Jacalyn Rosenblatt, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Eligibility Criteria
This trial is for adults over 18 with Acute Myelogenous Leukemia (AML) who've had a recent allogeneic transplant. They must be in remission, have good organ function, and not have severe ongoing graft-versus-host disease or other serious illnesses. Participants need to agree to use birth control and can't be on non-FDA approved study drugs or have autoimmune diseases needing steroids.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the DC/AML fusion cell vaccine and decitabine post-transplant
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- DC/AML Fusion Vaccine
- Decitabine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Beth Israel Deaconess Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Dana-Farber Cancer Institute
Collaborator